News about

Is There a Pill For That? Forest Labs’ Iffy Pipeline

Tue, 21 May 2013 09:27:09 -0400

Pharma M&A – Actavis to Acquire Warner Chilcott

Mon, 20 May 2013 11:32:13 -0400

On Monday, generic drug maker Actavis Inc. (NYSE: ACT) announced plans to purchase specialty pharmaceutical company Warner Chilcott (NASDAQ: WCRX) in an all-stock deal valued around $8.5 billion. Actavis management will lead the combined company.

The move is particularly notable for Actavis, a company that has spurned

Forest Labs Will Present Data from Cariprazine and Levomilnacipran Phase 3 Trials at American Psychiatric Association Annual Meeting

Thu, 16 May 2013 08:01:46 -0400

Forest Laboratories, Inc. (NYSE: FRX), today announced it will be presenting data on two late-stage development products, cariprazine and levomilnacipran, at the American Psychiatric Association (APA) annual meeting scheduled May 18-22, 2013, in San Francisco, CA. Data on cariprazine, an investigational antipsychotic agent, provides details from Phase 3 trials for schizophrenia and acute

Forest-Trevena Ink Deal – Analyst Blog

Tue, 14 May 2013 12:40:01 -0400

TRV027 is being developed for the treatment of acute decompensated heart failure.

(FRX) Forest Laboratories Sees Positive Data on Combo Drug

Tue, 07 May 2013 17:22:29 -0400

Forest Laboratories, Inc. (FRX) and Almirall, S.A. recently announced positive top-line data on...

Visit StockBlogHub to view complete post.

Positive Data on Forest Combo Drug – Analyst Blog

Tue, 07 May 2013 17:00:01 -0400

With two phase III studies generating positive results, Forest intends to file for US and EU approval in the fourth quarter of 2013.

Forest Laboratories and Almirall Announce Positive Results for the Second Phase III Study for Aclidinium and Formoterol combination in COPD

Wed, 01 May 2013 14:18:01 -0400

Forest Laboratories (NYSE: FRX) and Almirall, S.A. (ALM:MC) today announced positive topline results from AUGMENT COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide (LAMA) and formoterol fumarate (LABA), delivered in the Pressair® (Genuair® outside

Hot Option Plays: Blue Chips Lag After Hours

Wed, 24 Apr 2013 18:18:02 -0400

After Hours 04-24-2013 Stock market averages shook off morning weakness along with disappointing economic data and are mostly higher late-Wednesday. A report released before the opening bell showed orders for durable goods falling by 5.7 percent in March, which was worse than the 3.1 percent decline that was expected. Excluding transports, orders fell 1.4 percent [...]

Loss Widens at Ironwood – Analyst Blog

Wed, 24 Apr 2013 17:00:01 -0400

Ironwood Pharmaceuticals reported first quarter 2013 loss of 87 cents.

Forest Labs’ Earnings Decline – Analyst Blog

Tue, 23 Apr 2013 15:10:01 -0400

Earnings declined due to the impact of the genericization of Lexapro.

Earnings Scheduled For April 23, 2013

Tue, 23 Apr 2013 04:41:40 -0400

AO Smith (NYSE: AOS) is estimated to report its Q1 earnings at $0.77 per share on revenue of $504.78 million.

Apple (NASDAQ: AAPL) is projected to post its Q2 earnings at $10.07 per share on revenue of $42.59 billion.

Air Products & Chemicals (NYSE: APD) is

Forest Labs Likely to Miss 4Q Earnings – Analyst Blog

Mon, 22 Apr 2013 13:00:01 -0400

We expect Forest Labs to miss earnings expectations when it reports fourth-quarter fiscal 2013 results on Apr 23, before the opening bell

Weekly Preview: Earnings Season Continues, Apple In Focus

Fri, 19 Apr 2013 16:38:35 -0400

Next week, earnings season continues as investors eye key earnings from technology behemoths Apple (NASDAQ: AAPL) and chip maker Texas Instruments (NASDAQ: TXN). Texas Instruments' earnings and guidance is considered a key indicator for the semiconductor, and the broader technology industry by many analysts.

Key Earnings Next

Positive Data on Forest Candidate – Analyst Blog

Thu, 18 Apr 2013 17:00:01 -0400

Positive results from another phase III study would allow Forest and Almirall to go ahead and seek marketing approval for the COPD treatment in the US and the EU.

(MRK) Pharma & Biotech Stock Outlook – Apr 2013 – Zacks Analyst Interviews

Sun, 07 Apr 2013 14:52:57 -0400

The pharmaceutical industry has been showing signs of recovery from one of the biggest patent...

Visit StockBlogHub to view complete post.

Barron's Recap (3/23/13): World's Best CEOs

Sun, 24 Mar 2013 13:12:00 -0400

This weekend in Barron's online: the annual list of the best chief executives in the world, and the prospects for Darden Restaurants, Sarepta Therapeutics and Seacor Holdings.

Cover Story

"World's Best CEOs" by Andrew Bary.

Barron's ninth annual list of the 30 best chief executives in the world includes leaders whose companies

NIRI Appoints Charles Triano to Board of Directors

Wed, 20 Mar 2013 09:39:30 -0400

The National Investor Relations Institute (NIRI) today announced the appointment of Charles (Chuck) Triano to the NIRI Board of Directors. Triano is Senior Vice President, Investor Relations, for Pfizer (NYSE: PFE), a leading global biopharmaceutical company. He replaces William (Bill) Walkowiak who retired and stepped down from the

UPDATE: Credit Suisse Raises PT to $44 on Forest Laboratories on Positive Linzess Survey

Fri, 15 Mar 2013 13:34:09 -0400

Credit Suisse maintained Forest Laboratories (NYSE: FRX) with an Outperform rating and raised the price target from $42.00 to $44.00.

Credit Suisse analyst Catherine Arnold noted, "Credit Suisse proprietary market research survey with approx. 100 physicians implies greater demand via both category expansion and competitive market share. Respondents include

You Wouldn’t Know it By Watching Network News . . .

Mon, 04 Mar 2013 14:33:53 -0500

Herbalife Soars as Icahn Reveals Huge Stake

Thu, 14 Feb 2013 20:12:41 -0500

Carl Icahn filed a quarterly 13-F after the closing bell on Thursday showing his firm's long equity positions. While his 13-F was largely unchanged versus last quarter, an SEC filing showed that the investor had accumulated a 12.98 percent stake in embattled multi-level marketer Herbalife (NYSE: HLF).

The

Benzinga's Top Initiations

Thu, 31 Jan 2013 07:59:36 -0500

Janney Capital initiated coverage on shares of Salix Pharmaceuticals (NASDAQ: SLXP) with a “buy” rating. The target price for Salix is set to $55. Salix's shares closed at $47.21 yesterday.

Analysts at Leerink initiated coverage on shares of Santarus (NASDAQ: SNTS) with a “outperform” rating. Santarus' shares

UPDATE: Bank of America Reiterates Buy Rating, Raises PT on Forest Laboratories

Wed, 30 Jan 2013 12:48:28 -0500

In a report published Wednesday, Bank of America reiterated its Buy rating on Forest Laboratories (NYSE: FRX), and raised its price target from $43.00 to $45.00.

Bank of America noted, “We commissioned a survey of 75 physicians that treat COPD to get a sense for current and future prescribing

Canada Approves Forest’s Bystolic – Analyst Blog

Tue, 22 Jan 2013 16:30:01 -0500

Bystolic, which is already approved and marketed in the US, will be launched in Canada in the second quarter of this year.

Health Canada Approves Forest Labs' BYSTOLIC for Hypertension

Thu, 17 Jan 2013 17:01:31 -0500

Forest Laboratories, Inc. (NYSE: FRX) announced today that its Canadian subsidiary, Forest Laboratories Canada Inc. has received a Notice of Compliance from Health Canada for BYSTOLIC® (nebivolol) tablets, a once daily beta blocker for the treatment of hypertension.

“We are pleased that Health Canada has granted approval for BYSTOLIC. This is an important

Loss Widens at IRWD on Higher Costs – Analyst Blog

Wed, 16 Jan 2013 10:40:01 -0500

Ironwood Pharmaceuticals reported fourth quarter 2012 loss of 41 cents per share

Company News for January 16, 2013 – Corporate Summary

Wed, 16 Jan 2013 09:36:01 -0500

Companies in the News are: FRX,LEN,CBSH,LULU

UPDATE: Deutsche Bank Reiterates Hold Rating, Raises PT on Forest Laboratories

Wed, 16 Jan 2013 09:20:44 -0500

In a report published Wednesday, Deutsche Bank reiterated its Hold rating on Forest Laboratories (NYSE: FRX), and raised its price target from $34.00 to $36.00.

Deutsche Bank noted, “FRX reported Q3 non-GAAP loss per share of $0.21, $0.10 wider than consensus, with lower than expected revs (-$40M vs consensus)

Market to Remain Tentative – Analyst Blog

Tue, 15 Jan 2013 10:07:01 -0500

The market's mood is expected to be tentative ahead of big bank earnings reports the rest of this week.

Ahead of Wall Street – January 15, 2012 – Ahead of Wall Street

Tue, 15 Jan 2013 09:55:01 -0500

A strong retail sales reading, weak economic growth in Germany, and reassuring words out of Ben Bernanke Monday evening provide the backdrop for today's trading action.

Forest Revs Down, Swings to Loss – Analyst Blog

Tue, 15 Jan 2013 08:54:01 -0500

Results were hit by the loss of exclusivity on Lexapro as well as the disappointing performance of Namenda.

Benzinga Market Primer: Tuesday, January 15

Tue, 15 Jan 2013 06:26:24 -0500

Futures Flat on Weak German GDP

U.S. equity futures traded fractionally lower in early Tuesday trade following the release of fourth quarter and full year 2012 GDP data for Germany. German GDP contracted 0.5 percent in the fourth quarter bringing the 2012 total rate of growth of +0.7 percent, weaker than

US Stock Futures Slightly Lower Ahead Of Economic Data

Tue, 15 Jan 2013 06:10:43 -0500

US stock futures are slightly lower this morning, as investors are awaiting economic data. Futures for the Dow Jones Industrial Average dropped 10 points to 13,423.00 and S&P 500 index futures fell 2.30 points to 1,462.00. Nasdaq 100 futures declined 3 points to 2,725.75.

US stocks closed mostly lower on Monday,

Stock futures flat ahead of retail, mfg. data

Tue, 15 Jan 2013 06:03:43 -0500

U.S. stock market futures point to a slightly lower start for Wall Street later with investors awaiting key retail sales data and the Empire State manufacturing index. Shares of Dell Inc. could stay in the spotlight after prior-day reports of private-sector buyout talks.

Big earnings Tuesday: Lennar, Interactive Brokers

Tue, 15 Jan 2013 05:30:43 -0500

Among the companies whose shares are expected to see active trade in Tuesday’s session are Lennar, Interactive Brokers, and Forest Laboratories.

Earnings Scheduled For January 15, 2013

Tue, 15 Jan 2013 02:06:47 -0500

Commerce Bancshares (NASDAQ: CBSH) is expected to report its Q4 earnings at $0.72 per share on revenue of $264.43 million.

Forest Laboratories (NYSE: FRX) is estimated to post a Q3 loss at $0.13 per share on revenue of $764.25 million.

Ironwood Pharmaceuticals (NASDAQ: IRWD) is projected

Stocks To Watch For January 15, 2013

Tue, 15 Jan 2013 01:32:24 -0500

Some of the stocks that may grab investor focus today are:

Wall Street expects Lennar (NYSE: LEN) to report its Q4 earnings at $0.44 per share on revenue of $1.32 billion. Lennar shares rose 0.41% to $41.19 in after-hours trading.

Dell (NASDAQ: DELL) is in talks to go

The Week Ahead: Financials in Focus

Fri, 11 Jan 2013 17:26:33 -0500

The second full week of January brings a barrage of earnings reports from U.S. corporations. In particular, investors will see results from most of the major U.S. banks including Citigroup (NYSE: C), Bank of America (NYSE: BAC) and Goldman Sachs (NYSE: GS).

It won't be

Straddling Earnings Season – Know Your Options

Thu, 10 Jan 2013 04:04:01 -0500

Straddling Earnings Season - Know Your Options

Forest Settles with Glenmark – Analyst Blog

Wed, 09 Jan 2013 17:00:01 -0500

Forest Laboratories recently entered into a settlement agreement with Glenmark Pharmaceuticals Ltd., relating to its patent infringement litigation for Bystolic.

Goldman Sachs and Others That May Beat Earnings

Tue, 08 Jan 2013 13:42:25 -0500

In this morning's Marketwatch alert on companies that may report earnings surprises for the fourth quarter, just three were expected to offer positive surprises.

Goldman Sachs (NYSE: GS) was seen beating the consensus estimate by up to 18 percent. Forest Laboratories (NASDAQ: FRX) could turn in

Spoiler alert: 9 stocks that may shock on earnings

Tue, 08 Jan 2013 06:00:14 -0500

These 9 stocks are likely to surprise on earnings, according to a data analysis that filters out estimate noise like stale forecasts. The financial sector could look ugly.

Top 4 Mid-Cap Stocks In The Drug Manufacturers-Other Industry With The Highest Cash

Tue, 08 Jan 2013 04:07:56 -0500

Below are the top mid-cap drug manufacturers-other stocks on the NYSE and the NASDAQ in terms of cash.

Forest Laboratories (NYSE: FRX) had $2.12 billion in total cash and no debt for the latest quarter.

Cubist Pharmaceuticals (NASDAQ: CBST) had $896.96 million in total cash for the latest

Ironwood Winds Up Debt Offering – Analyst Blog

Mon, 07 Jan 2013 17:50:01 -0500

Ironwood Pharmaceuticals announced that it has completed the offering of Linaclotide PhaRMA 11% notes

Positive Results on SGYP Candidate – Analyst Blog

Thu, 03 Jan 2013 16:30:01 -0500

Synergy Pharma presented positive results from a phase IIb/III study on its CIC candidate, plecanatide

Ironwood Pharma Upped to Strong Buy – Analyst Blog

Thu, 03 Jan 2013 14:14:01 -0500

Zacks Investment Research upgraded Ironwood Pharmaceuticals to a Zacks Rank #1

(FRX) Synergy Pharmaceuticals Shows Pipeline Progress

Tue, 01 Jan 2013 19:39:45 -0500

Synergy Pharmaceuticals (SGYP) recently initiated a phase IIb study with plecanatide for the...

Visit StockBlogHub to view complete post.

Pipeline Progress at Synergy Pharma – Analyst Blog

Mon, 31 Dec 2012 13:02:01 -0500

Synergy Pharma initiated a phase IIb study with plecanatide for the treatment of patients suffering from IBS-C

Forest Labs-Glenmark Tie Up – Analyst Blog

Mon, 31 Dec 2012 09:00:01 -0500

The companies will work on the development of novel mPGES-1 inhibitors for the treatment of chronic inflammatory conditions, including pain.

Ironwood Anxiety Drug in Phase I – Analyst Blog

Thu, 27 Dec 2012 17:37:01 -0500

IW-2143's safety and pharmacokinetics will be evaluated in the study.

Forest Launches Two Products – Analyst Blog

Wed, 19 Dec 2012 11:10:01 -0500

Forest Labs launched Linzess and Tudorza in the US.